AzTrials
AzTrials

Hemophilia APhase 4JOIN-usNCT05856266

An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa

A Phase 4 study testing Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS) in people with Hemophilia A and Hemophilia B, run by Swedish Orphan Biovitrum at 56 sites in 11 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc. Read more about this study

Who is it for?
Ages 6 years and older
Conditions the study is for
Hemophilia A, Hemophilia B
What is being tested?
Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
56 sitesin 11 countries
Study dates
24 Aug 2023to 6 Dec 2023
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Age ≥ 6 years
  • Diagnosis of haemophilia A or B
  • Having at least 6 months documented pre-study treatment data regarding treatment prescriptions and bleeding episodes prior to the baseline visit
  • Previous treatment for haemophilia A or B with any marketed recombinant and/or plasma-derived FVIII or FIX concentrate for at least 6 months
  • Start of prophylactic treatment with rFVIIIFc or rFIXFc prior to study enrollment or latest at the baseline visit, in accordance with local regulations
  • Signed and dated informed consent provided by the patient, or the patient's legally authorized representative for patients under the legal age. Assent should be obtained from paediatric patients in accordance with local regulations

Who cannot join

  • Any medical condition which in the opinion of the investigator makes the subject patient unsuitable for inclusion
  • Prophylactic treatment with non-factor therapy during the 6 months prior to enrolment
  • Presence of factor VIII or FIX inhibitory antibodies (inhibitors) (≥0.60 Bethesda Units [BU]/mL) at the latest available inhibitor test
  • Enrolment in a concurrent clinical interventional study, or intake of an IMP, within three months prior to inclusion in this study
  • Foreseeable inability to cooperate with given instructions or study procedures

Trial locations and contacts

56 sites in 11 countries.

56 sites in 11 countries

France20 sites
  • Study site 115

    Bordeaux

  • Study site 129

    Caen

  • Study site 125

    Chambéry

  • Study site 110

    Clermont-Ferrand

  • Study site 123

    Dijon

  • Study site 124

    Lille

  • Study site 111

    Lyon

  • Study site 126

    Marseille

  • Study site 120

    Nancy

  • Study site 121

    Nantes

  • Study site 113

    Nîmes

  • Study site 119

    Paris

  • Study site 130

    Paris

  • Study site 118

    Poitiers

  • Study site 117

    Reims

  • Sudy site 122

    Rennes

  • Study site 109

    Rouen

  • Study site 112

    Strasbourg

  • Study site 128

    Toulouse

  • Study site 114

    Tours

Other trials in France

Spain10 sites
  • Study site 151

    A Coruña

  • Study site 150

    Alicante

  • Study site 152

    Barcelona

  • Study site 149

    Madrid

  • Study site 154

    Málaga

  • Study site 156

    Oviedo

  • Study site 153

    Salamanca

  • Study site 157

    Valencia

  • Study site 155

    Valladolid

  • Study site 158

    Zaragoza

Other trials in Spain

Italy7 sites
  • Study site 136

    Bologna

  • Study site 134

    Brescia

  • Study site 138

    Catania

  • Study site 140

    Milan

  • Study site 137

    Palermo

  • Study site 135

    Pisa

  • Study site 139

    Vicenza

Other trials in Italy

Czechia5 sites
  • Study site 108

    Brno

  • Study site 107

    Liberec

  • Study site 104

    Olomouc

  • Study site 105

    Prague

  • Study site 106

    Prague

Other trials in Czechia

Romania5 sites
  • Study site 145

    Baia Mare

  • Study site 141

    Bucharest

  • Study site 143

    Craiova

  • Study site 146

    Iași

  • Study site 142

    Timișoara

Other trials in Romania

Bulgaria2 sites
  • Study site 100

    Sofia

  • Study site 101

    Sofia

Other trials in Bulgaria

Croatia2 sites
  • Study site 102

    Zagreb

  • Study site 103

    Zagreb

Other trials in Croatia

Ireland2 sites
  • Study site 132

    Dublin

  • Study site 133

    Dublin

Other trials in Ireland

Hungary1 site
  • Study site 131

    Budapest

Other trials in Hungary

Slovenia1 site
  • Study site 147

    Ljubljana

Other trials in Slovenia

United Kingdom1 site
  • Study site 159

    Belfast

Other trials in United Kingdom

About this study

Official title: An 18-month Low-interventional Prospective, Multicentre Study to Assess Joint Outcomes in Patients With Haemophilia A or B on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa

The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc.

The main question it aims to answer is the:

Read more
  • Evaluation of the overall joint status as detected by ultrasound in haemophilia A and B patients treated with rFVIIIFc or rFIXFc prophylaxis over the 18-month study period.

Participants will come to 6-monthly visits during the 18-month long study period and will perform an ultrasound with the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) protocol at each visit. At baseline and end of study visits, the patients will be assessed with the clinical scoring system Haemophilia Joint Health Score (HJHS) and complete patient questionnaires. Retrospective data from patient medical records will also be collected for at least 6 months before enrolment in the study.

Read the detailed description

The main purpose of this study is to prospectively describe the joint health over an 18-month period of prophylactic treatment with rFVIIIFc or rFIXFc in patients with haemophilia A or haemophilia B in a real-world setting in Europe.

This is a low-interventional, multicentre study using point-of-care US examination for regular monitoring of joint health and detection of hypertrophic synovium, cartilage and bone damage. At the same time, clinical joint status will also be examined by HJHS. This study will evaluate the presence, resolution, recurrence, and new development of target joints. It will also describe bleeding episodes and evaluate the quality of life and physical activity with PROs. If patients are using the CE marked Florio HAEMO app in their routine clinical practice, they will be offered to participate in an optional sub-study that aims to explore possible correlations between the levels of physical activity, the estimated FVIII/FIX levels and bleeding occurrence.

Being tested
Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US), Haemophilia Joint Health Score (HJHS)
Keywords
Blood coagulation disorder, Coagulation protein disorder, Haemophilia, FVIII, FIX, Efmoroctocog alfa, Eftrenonacog alfa
Medical subject headings
Hemophilia A, Hemophilia B, Blood Coagulation Disorders, Coagulation Protein Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)Procedure or surgery

    Ultrasound examination

  • Haemophilia Joint Health Score (HJHS)Other

    Functional joint examination

Study groups in NCT05856266
Study groupRoleWhat they receive
Efmoroctocog alfa or eftrenonacog alfaOtherEfmoroctocog alfa or eftrenonacog alfa is prescribed and used according to usual clinical practice.
Receives: Procedure: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Other: Haemophilia Joint Health Score (HJHS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Total HEAD-US Score up to Month 18 (End of Study - EOS)

    HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.

    The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). The specific joint score is made up of three item scores: disease activity (synovitis), disease damage of articular surfaces, and disease damage of subchondral bone. The specific joint score is the sum of the three item scores for each specific joint. Its values range from 0 (minimum) to 8 (maximum). The total score represents the sum of item scores for abnormalities detected.

    Measured: Baseline and month 18

Secondary outcomes (14)
  1. Change From Baseline in HEAD-US Score for Hypertrophic Synovium

    HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.

    The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). The disease activity (synovitis) score rates the status of the hypertrophic synovium. Hypertrophic synovium is graded in three steps (0: absent/minimal; 1: mild/moderate [score=1], 2: severe [score=2]) based on the comprehensive evaluation of the joint recesses and the mean amount of synovial tissue contained in them.

    Measured: Baseline, month 6, 12 and 18

  2. Change From Baseline in HEAD-US Score for Cartilage

    HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.

    The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). Concerning the articular cartilage, the damage is graded in five steps (0: normal; 1: echotexture abnormalities and focal loss involving <25% of the target surface [score=1]; 2: partial/full-thickness loss of the cartilage involving at least 50% of the target surface [score=2]; 3: partial/full-thickness loss of the cartilage involving >50% of the target surface [score=3]; 4: complete cartilage destruction or absent visualization of the articular cartilage on the target surface [score=4]).

    Measured: Baseline, month 6, 12 and 18

  3. Change From Baseline in HEAD-US Score for Bone

    HEAD-US is a standardized, fast, repeatable, and simple ultrasound scoring protocol for hemophiliac joints.

    The HEAD-US joint score will be calculated for the six index joints (elbows, knees, and ankles). Damage of subchondral bone is scored using a three-grade scale (0: normal; 1: mild irregularities of the subchondral bone with/without initial osteophytes around the joint [score=1]; 2: deranged subchondral bone with/without erosions and presence of prominent osteophytes around the joint [score=2]).

    Measured: Baseline, month 6, 12 and 18

  4. Change From Baseline in Total Hemophilia Joint Health Score (HJHS) at Month 18 (EOS)

    The HJHS measures joint health, in the domain of body structure and function (i.e., impairment). The six index joints (elbows, knees, and ankles) will be examined and scored. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits.

    The total score will be the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease).

    Measured: Baseline and month 18

  5. Number of Target Joints

    A target joint is defined as a joint with three or more spontaneous bleeds into the joint within a consecutive 6-month period. The study will evaluate the presence, resolution, recurrence, and new development of target joints.

    Measured: Baseline, month 6, 12 and 18

  6. Location of Target Joints

    A target joint is defined as a joint with three or more spontaneous bleeds into the joint within a consecutive 6-month period. The study will evaluate the presence, resolution, recurrence, and new development of target joints.

    Measured: Baseline, month 6, 12 and 18

  7. Total Annualized Bleeding Rate (ABR)

    For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location (e.g., muscle, joint, other), date of bleeding episode, dose (IU) and number of injections used to treat the bleed.

    Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period

  8. Joint ABR

    For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location, date of bleeding episode, dose (IU) and number of injections used to treat the bleed.

    Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period

  9. Target Joint ABR

    For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location, date of bleeding episode, dose (IU) and number of injections used to treat the bleed.

    Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period

  10. Traumatic/Spontaneous ABR

    For any bleeding episode, the following will be collected: bleeding episode circumstance (e.g., spontaneous, traumatic), bleeding episode location (e.g., muscle, joint, other), date of bleeding episode, dose (IU) and number of injections used to treat the bleed.

    Measured: 6 months retrospective period to baseline, baseline to 6 months, 6-12 months, 12-18 months and entire study period

  11. PROMIS Physical Function/Activity Short Form 6b and 8a Scores

    Patient-Reported Outcomes Measurement Information System (PROMIS) is a validated system of reliable and precise measures of patient-reported health status. PROMIS measures cover physical, mental, and social health, use a 5-point Likert response scale and a recall period of the past 7 days. The Numeric Rating Scale measures for adults (6b) consist of a single item rating physical function on average over the past 7 days, ranging from 5 (without any difficulty) to 1 (unable to do). Lower scores mean a worse outcome.

    The Numeric Rating Scale measures for pediatric and parent proxy (8a) each consist of a single item rating physical activity on average over the past 7 days, ranging from 1 (no days) to 5 (6-7 days). Lower scores mean a worse outcome.

    Measured: Baseline and 18 months

  12. PROMIS Pain Intensity 3a and 1a Scores

    Patient-Reported Outcomes Measurement Information System (PROMIS) is a validated system of reliable and precise measures of patient-reported health status. PROMIS measures cover physical, mental, and social health, use a 5-point Likert response scale and a recall period of the past 7 days. The Numeric Rating Scale measures for adults (3a) consist of a single item rating pain over the past 7 days from 1 (had no pain) to 5 (very severe). Higher scores mean a worse outcome. The Numeric Rating Scale measures for pediatric and parent proxy (1a) each consist of a single item rating pain over the past 7 days, ranging from 0 (no pain) to 10 (worst pain you can think of). Higher scores mean a worse outcome.

    Measured: Baseline and month 18

  13. PROMIS Pain Interference Short Form 6a and 8a Scores

    Patient-Reported Outcomes Measurement Information System (PROMIS) is a validated system of reliable and precise measures of patient-reported health status. PROMIS measures cover physical, mental, and social health, use a 5-point Likert response scale and a recall period of the past 7 days. The Numeric Rating Scale measures (adult, pediatric, parent proxy) each consist of a single item rating pain interference with different activities over the past 7 days, ranging from 1 (not at all/never) to 5 (very much/almost always). Higher scores mean a worse outcome.

    Measured: Baseline and month 18

  14. IPAQ-SF Scores

    International Physical Activity Questionnaire - Short Form (IPAQ-SF). The IPAQ-SF is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week, as well as categorization into high, moderate, or low physical activity level. Higher scores mean higher physical activity level (better outcome).

    Measured: Baseline and month 18

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 May 2023
  2. Study start24 Aug 2023
  3. Primary completion6 Dec 2023
  4. Study completion6 Dec 2023

Why it stopped: The Sponsor has decided to stop the phase 4 study Sobi.HAEM89-007 (JOIN-us) due to a realignment of its development activities. The clinical trial hasn't been terminated due to a change in the benefit-risk balance.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
This is a low-interventional study, with the drugs being prescribed and used according to clinical practice. The interventions in the study are the addition of the mandatory joint examinations HEAD-US (ultrasound) and HJHS (functional joint assessment).
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05856266
Sponsor's protocol ID
Sobi.HAEM89-007
Other IDs
2022-502921-16-00
Acronym
JOIN-us
Status last verified
Jan 2025
First submitted
24 Apr 2023
Last updated
16 Jan 2025
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS) in people with Hemophilia A and Hemophilia B, run by Swedish Orphan Biovitrum at 56 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 16 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 56 sites in France, Spain, Italy, Czechia, Romania and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Total HEAD-US Score up to Month 18 (End of Study - EOS) (time frame: Baseline and month 18). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in